TY - JOUR
T1 - Thirty years of BCL-2
T2 - Translating cell death discoveries into novel cancer therapies
AU - Delbridge, Alex R. D.
AU - Grabow, Stephanie
AU - Strasser, Andreas
AU - Vaux, David L.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows that therapies designed to counter these alterations might be effective as anti-cancer strategies. Over the past 30 years, research on the BCL-2-regulated apoptotic pathway has led to the development of small-molecule compounds, known as 'BH3-mimetics', that bind to pro-survival BCL-2 proteins to directly activate apoptosis of malignant cells. This Timeline article focuses on the discovery and study of BCL-2, the wider BCL-2 protein family and, specifically, its roles in cancer development and therapy.
AB - The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows that therapies designed to counter these alterations might be effective as anti-cancer strategies. Over the past 30 years, research on the BCL-2-regulated apoptotic pathway has led to the development of small-molecule compounds, known as 'BH3-mimetics', that bind to pro-survival BCL-2 proteins to directly activate apoptosis of malignant cells. This Timeline article focuses on the discovery and study of BCL-2, the wider BCL-2 protein family and, specifically, its roles in cancer development and therapy.
UR - http://www.scopus.com/inward/record.url?scp=84956630703&partnerID=8YFLogxK
U2 - 10.1038/nrc.2015.17
DO - 10.1038/nrc.2015.17
M3 - Review Article
AN - SCOPUS:84956630703
SN - 1474-175X
VL - 16
SP - 99
EP - 109
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 2
ER -
